Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 3, 2010, Pages 1235-1240

  Choi, Chung Hang J ^a   Alabi, Christopher A ^a,c   Webster, Paul ^b   Davis, Mark E ^a  

^a California Institute of Technology   (United States)

^b HOUSE EAR INSTITUTE   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

In vivo distribution; Intracellular localization; Ligand content; Targeted delivery

Indexed keywords

GOLD NANOPARTICLE; LIGAND; TRANSFERRIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER CELL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HISTOPATHOLOGY; LIVER; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SOLID TUMOR;

ANIMALS; BINDING, COMPETITIVE; DRUG DELIVERY SYSTEMS; FEMALE; GOLD; LIVER; MASS SPECTROMETRY; METAL NANOPARTICLES; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; NEOPLASMS, EXPERIMENTAL; PARTICLE SIZE; TRANSFERRIN;

MUS;

EID: 75749088450     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0914140107     Document Type: Article

References (27)

1. Davis ME, Chen ZG, Shin DM (2008) Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat Rev Drug Discov 7:771-782.
2. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res 46:6387-6392.
3. Dreher MR, et al. (2006) Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 98:335-344.
4. Lopes de Menezes DE, Pilarski LM, Allen TM (1998) In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 58:3320-3330.
5. Zhou Y, et al. (2007) Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J Mol Biol 371:934-947.
6. Farokhzad OC, et al. (2004) Nanoparticle-aptamer bioconjugates: A new approach for targeting prostate cancer cells. Cancer Res 64:7668-7672.
7. Bhattacharya R, et al. (2007) Attaching folic acid on gold nanoparticles using noncovalent interaction via different polyethylene glycol backbones and targeting of cancer cells. Nanomed Nanotechnol Biol Med 3:224-238.
8. Montet X, Funovics M, Montet-Abou K, Weissleder R, Josephson L (2006) Multivalent effects of RGD peptides obtained by nanoparticle display. J Med Chem 49:6087-6093.
9. Popielarski SR, Pun SH, Davis ME (2005) A nanoparticle-based model delivery system to guide the rational design of gene delivery to the liver. 1. Synthesis and characterization. Bioconjug Chem 16:1063-1070.
10. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WC (2009) Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett 9:1909-1915.
11. Park JW, et al. (2002) Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8:1172-1181.
12. Kirpotin DB, et al. (2006) Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 66:6732-6740.
13. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME (2007) Impact of tumorspecific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA 104:15549-15554.
14. Schmidt MM, Wittrup KD (2009) A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 8:2861-2871.
15. Thomas M, Klibanov AM (2003) Conjugation to gold nanoparticles enhances polyethylenimine's transfer of plasmid DNA into mammalian cells. Proc Natl Acad Sci USA 100:9138-9143.
16. Frens G (1972) Controlled nucleation for the regulation of the particle size in monodisperse gold suspensions. Nat Phys Sci 241:20-22.
17. Danscher G (1981) Histochemical demonstration of heavy metals. Histochemistry 71:1-16.
18. De Jong WH, et al. (2008) Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials 29:1912-1919.
19. Yang M, Yau HCM, Chan HL (1998) Adsorption kinetics and ligand-binding properties of thiol-modified double-stranded DNA on a gold surface. Langmuir 14:6121-6129.
20. Kubetzko S, Sarkar CA, Plückthun A (2005) Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Mol Pharmacol 68:1439-1454.
21. Ishida O, et al. (2001) Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm Res 18:1042-1048.
22. Gatter KC, Brown G, Trowbridge IS, Woolston RE, Mason DY (1983) Transferrin receptors in human tissues: Their distribution and possible clinical relevance. J Clin Pathol 36:539-545.
23. Sawyer ST, Krantz SB (1986) Transferrin receptor number, synthesis, and endocytosis during erythropoietin-induced maturation of Friend virus-infected erythroid cells. J Biol Chem 261:9187-9195.
24. Stein BS, Sussman HH (1983) Peptide mapping of the human transferrin receptor in normal and transformed cells. J Biol Chem 258:2668-2673.
25. Enns CA, Rutledge EA, Williams AM (1996) The transferrin receptor. Biomembranes 4:255-287.
26. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ (2005) Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 65:8984-8992.
27. Jiang W, Kim BYS, Rutka JT, Chan WCW (2008) Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol 3:145-150.